These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25905926)

  • 1. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
    Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.
    Krajewski KM; Braschi-Amirfarzan M; DiPiro PJ; Jagannathan JP; Shinagare AB
    Korean J Radiol; 2017; 18(1):28-41. PubMed ID: 28096716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in metastatic esophageal cancer: advances over the past decade.
    Mohamed A; El-Rayes B; Khuri FR; Saba NF
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):186-96. PubMed ID: 24582516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy and elderly people: A review.
    Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P
    Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
    Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
    Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S; Saif MW
    Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapy in older patients with solid tumors.
    Kelly CM; Power DG; Lichtman SM
    J Clin Oncol; 2014 Aug; 32(24):2635-46. PubMed ID: 25071113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel chemotherapeutic approaches in adult high-grade gliomas.
    Jordan JT; Wen PY
    Cancer Treat Res; 2015; 163():117-42. PubMed ID: 25468229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 13. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular signaling and the role of targeted therapies in bladder cancer.
    Black PC
    Minerva Urol Nefrol; 2012 Mar; 64(1):7-17. PubMed ID: 22402314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.